Strainsforpains, Inc. — Cyborg Score 4/10

Mixed
Cannabis health data platforms

Strategic Profile

Strainsforpains is a medical marijuana recommendation engine that guides patients to the appropriate cannabinoid levels, medical cannabis strains, and consumption methods for their specific ailment. The company owns a 6.5-acre facility in Pennsylvania that will be used for CBD product production, and has a strategic partnership with GenBio, Inc. to license anti-inflammatory compounds in Strainsforpains CBD branded products.

Cyborg Score Rationale

Strainsforpains operates in a growing cannabis/wellness tech sector with differentiated IP and strategic partnerships, but faces significant headwinds as a micro-cap OTC company with only 2 employees and limited revenue visibility. Limited public disclosure and early-stage commercialization suggest operational risk.

Top Insights

  • Patent-pending AI recommendation technology positions the company to become an industry standard for cannabis-related selection and data across regulated and unregulated markets
  • Dual revenue strategy combining high-margin software/app licensing with physical CBD product sales addresses both B2B (hospitals, dispensaries) and B2C (direct consumer) channels
  • (January 2024) Closed 2023 with largest orders to date valued at $65,000 from NYC establishments and anticipated $600,000 in sales by end of 2024 through Popped partnership
  • Water-soluble nanoliposomal CBD technology claimed to increase absorption by 80% differentiates topical product line in competitive cannabis market

Named Competitors

  • Leafly — Cannabis product discovery and dispensary locator platform
  • Weedmaps — Cannabis delivery and dispensary marketplace
  • Charlottes Web — Premium CBD product manufacturer and retailer

Recent Developments

  • (January 2024) Announced largest orders to date valued at $65,000 from NYC establishments including Forces of Nature and Portokali
  • (January 2024) Established collaboration with Popped (NYC company) with anticipated joint product sales of $600,000 by end of 2024

Open the full interactive Strainsforpains, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →